

Krzysztof Domka

Lista publikacji

1. Domka K, Dabkowska A, Janowska M et al. (2024). Asciminib stands out as the superior tyrosine kinase inhibitor to combine with CD20-targeted monoclonal antibodies for the treatment of CD20+ Philadelphia+ B-cell precursor acute lymphoblastic leukemia in preclinical models, *Haematologica*, Early View, <https://doi.org/10.3324/haematol.2023.284853>
2. Fidyt, K., Pastorczak, A., Cyran, J. et al. (2022). Potent, p53-independent induction of NOXA sensitizes MLL-rearranged B-cell acute lymphoblastic leukemia cells to venetoclax. *Oncogene* 41(11), 1600–1609 <https://doi.org/10.1038/s41388-022-02196-y>
3. Pastorczak A, Domka K, Fidyt K, et al. (2021). Mechanisms of Immune Evasion in Acute Lymphoblastic Leukemia, *Cancers*, 13(7):1536. <https://doi.org/10.3390/cancers13071536>
4. Domka K, Góral A, Firczuk M (2020). cROSSing the Line: Between Beneficial and Harmful Effects of Reactive Oxygen Species in B-Cell Malignancies. *Frontiers in Immunology*, 11:1538. <https://doi.org/10.3389/fimmu.2020.01538>,
5. Dąbkowska A, Domka K, Firczuk M (2024). Advancements in cancer immunotherapies targeting CD20: from pioneering monoclonal antibodies to chimeric antigen receptor-modified T cells. *Frontiers in Immunology* 15:1363102. <https://doi.org/10.3389/fimmu.2024.1363102>